Karyopharm Therapeutics
Christopher Roche has a Bachelor of Science in Business Administration from Bryant University. Currently, Christopher Roche is pursuing a Masters in Health Administration from Suffolk University - Sawyer Business School. In terms of work experience, Christopher Roche has held various roles in Market Access Operations, Commercial Analytics, and Financial Analysis at companies such as Karyopharm Therapeutics Inc., Sunovion Pharmaceuticals, Ironwood Pharmaceuticals, and Biogen Idec.
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).